Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 290 recommendations for 88 medicines and 23 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
8. Immunomodulators and antineoplastics
  1. Abemaciclib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast
  2. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
    Indications
    Malignant neoplasms of prostate
  3. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
  4. Afatinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  5. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  6. Allopurinol General information
    Section
    Supportive medicines
    • Oral > Solid: 100 mg; 300 mg
    Indications
    Tumour lysis syndrome
  7. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  8. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  9. Asparaginase General information
    Section
    Cytotoxic medicines
    • Powder for injection: 10 000 IU in vial.
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified
  10. Atezolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung
  11. Axicabtagene ciloleucel General information
    Section
    Antineoplastics and supportive medicines
    • Cell suspension for infusion: 2 × 10*6 anti-CD19 CAR-positive viable T-cells per kg of body weight.
    Indications
    Diffuse large B-cell lymphomas
  12. Azacitidine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
    Myeloid leukaemia
  13. Azathioprine General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid > tablet: 25 mg; 50 mg (scored)
    • Oral > Solid > tablet: 50 mg (scored)
    Indications
    Failure or rejection of transplanted organs or tissues Relapsing-remitting multiple sclerosis
  14. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma
  15. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
    Indications
    Malignant neoplasms of prostate
  16. Binimetinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib for Other specified melanoma of skin
  18. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
    Indications
    Plasma cell myeloma
  19. Calcium folinate (leucovorin calcium) General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 15 mg tablet
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
    • Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
    • Oral > Solid > tablet: 15 mg; 5 mg; 25 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasm metastasis in large intestine Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of rectum Malignant neoplasms of colon
  22. Cemiplimab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung
  23. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  25. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Liquid: 100 mg per mL
    • Oral > Solid > capsule: 25 mg
    Indications
    Failure or rejection of transplanted organs or tissues
  27. Cladribine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial
    Indications
    Langerhans cell histiocytosis
  28. Cobimetinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to trametinib for Other specified melanoma of skin
  29. Crizotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 200 mg; 250 mg
    • Oral > Solid > capsule: 200 mg; 250 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung Anaplastic large cell lymphoma, ALK-positive
  30. Cyclophosphamide General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 25 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Oral > Solid > dosage form: 25 mg; 50 mg
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of breast Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of breast Chronic lymphocytic leukaemia or small lymphocytic lymphoma Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Other specified gliomas of brain Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  32. Dabrafenib General information
    Section
    Targeted therapies
    • Oral > Solid: 50 mg; 75 mg
    Indications
    Other specified melanoma of skin
  33. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection
    Indications
    Hodgkin lymphoma
  35. Daratumumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
    Indications
    Plasma cell myeloma
  36. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  37. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia
  38. Dexamethasone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Indications
    Plasma cell myeloma Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  40. Doxorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
    • Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Rhabdomyosarcoma primary site Malignant neoplasms of breast Hodgkin lymphoma Diffuse large B-cell lymphomas Plasma cell myeloma Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Anaplastic large cell lymphoma, ALK-negative Other specified malignant neoplasms of breast Anaplastic large cell lymphoma, ALK-positive Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site
  41. Doxorubicin (as pegylated liposomal) General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
    Indications
    Kaposi sarcoma of unspecified primary site
  42. Durvalumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 120 mg per 2.4 mL in vial; 500 mg per 10 mL in vial
    Indications
    Other specified malignant neoplasms of bronchus or lung
  43. Encorafenib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib for Other specified melanoma of skin
  44. Enzalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 40 mg
    Indications
    Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate Malignant neoplasms of prostate
  45. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
    Indications
    Other specified malignant neoplasms of bronchus or lung
  46. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  47. Etoposide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
    • Oral > Solid: 100 mg capsule
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
    • Oral > Solid: 100 mg capsule; 50 mg capsule
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Germ cell tumour of testis Malignant trophoblastic neoplasms of placenta Malignant neoplasms of kidney, except renal pelvis Osteosarcoma of bone and articular cartilage of unspecified sites Hodgkin lymphoma Retinoblastoma Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative
  48. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
    • Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg
    Indications
    Other specified gliomas of brain
  49. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  50. Fingolimod General information
    Section
    Immunomodulators for non-malignant disease
    • Oral > Solid: 0.25 mg; 0.5 mg
    Indications
    Relapsing-remitting multiple sclerosis
  51. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  53. Flutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  54. Fulvestrant General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 250 mg per 5 mL
    Indications
    Malignant neoplasms of breast
  55. Gefitinib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung
  56. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
    Indications
    Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung
  57. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  58. Goserelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  59. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia
  60. Hydroxycarbamide (hydroxyurea) General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
    • Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
    Indications
    Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified
  61. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
    Indications
    Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  62. Ifosfamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
    Indications
    Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive
  64. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  65. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site
  66. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
    Indications
    Plasma cell myeloma
  67. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
    Indications
    Malignant neoplasms of breast Malignant neoplasms of prostate
  68. Lisocabtagene maraleucel General information
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas
  69. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
    Indications
    Plasma cell myeloma
  72. Methotrexate General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
    • Oral > Solid: 2.5 mg (as sodium salt)
    • Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified Acute myeloid leukaemia with recurrent genetic abnormalities Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Osteosarcoma of bone and articular cartilage of unspecified sites Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive Langerhans cell histiocytosis
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: pre-filled syringe in multiple strengths
    Indications
    Crohn disease site Psoriatic arthritis
  73. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
    Indications
    Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia
  74. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid > capsule: 150 mg; 200 mg
    Indications
    Chronic myeloid leukaemia, not elsewhere classified
  75. Nilutamide General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to bicalutamide for Malignant neoplasms of prostate
  76. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
    Indications
    Other specified malignant neoplasms of bronchus or lung Melanoma of skin
  77. Osimertinib General information
    Section
    Targeted therapies
    • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)
    Indications
    Other specified malignant neoplasms of bronchus or lung
  78. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
    Indications
    Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon
  80. Palbociclib General information
    Section
    Targeted therapies
    • Oral > Solid: 75 mg; 100 mg; 125 mg
    Indications
    Other specified malignant neoplasms of breast
  81. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  82. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  83. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg powder for injection
    Indications
    Therapeutic equivalent to nivolumab for Melanoma of skin Other specified malignant neoplasms of bronchus or lung
  84. Pertuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution
    Indications
    Carcinoma of breast, specialised type
  86. Prednisone General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to prednisolone for Plasma cell myeloma Therapeutic equivalent to prednisolone for Follicular lymphoma Therapeutic equivalent to prednisolone for Lymphoid leukaemia, not elsewhere classified Therapeutic equivalent to prednisolone for Malignant neoplasms of prostate Therapeutic equivalent to prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Therapeutic equivalent to prednisolone for Hodgkin lymphoma Therapeutic equivalent to prednisolone for Diffuse large B-cell lymphomas Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-negative Therapeutic equivalent to prednisolone for Anaplastic large cell lymphoma, ALK-positive Therapeutic equivalent to prednisolone for Langerhans cell histiocytosis
  87. Procarbazine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 50 mg (as hydrochloride)
    • Oral > Solid > capsule: 50 mg (as hydrochloride)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Hodgkin lymphoma
  88. Rasburicase General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 1.5 mg in vial powder and solvent for solution; 7.5 mg in vial powder and solvent for solution
    Indications
    Tumour lysis syndrome
  89. Realgar-indigo naturalis formulation General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)
    Indications
    Acute myeloid leukaemia with recurrent genetic abnormalities
  90. Ribociclib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast
  91. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphomas Burkitt lymphoma including Burkitt leukaemia
  92. Tacrolimus General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
    • Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
    • Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)
    Indications
    Failure or rejection of transplanted organs or tissues
  93. Tamoxifen General information
    Section
    Hormones and antihormones
    • Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)
    Indications
    Other specified malignant neoplasms of breast Malignant neoplasms of breast
  94. Thalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 50 mg
    Indications
    Plasma cell myeloma
  95. Tioguanine General information
    Section
    Cytotoxic medicines
    • Oral > Solid: 40 mg
    Indications
    Lymphoid leukaemia, not elsewhere classified
  96. Tisagenlecleucel General information
    Section
    Antineoplastics and supportive medicines
    Indications
    Therapeutic equivalent to axicabtagene ciloleucel for Diffuse large B-cell lymphomas
  97. Tislelizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 10 mL
    Indications
    Malignant neoplasms of urinary tract Hodgkin lymphoma Other specified malignant neoplasms of bronchus or lung
  98. Toripalimab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 240 mg per 6 mL in vial
    Indications
    Malignant neoplasms of nasopharynx Malignant neoplasms of oesophagus
  99. Trametinib General information
    Section
    Targeted therapies
    • Oral > Solid: 0.5 mg; 2 mg
    Indications
    Other specified melanoma of skin
  100. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  101. Trastuzumab emtansine General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  102. Triptorelin General information
    Section
    Hormones and antihormones
    Indications
    Therapeutic equivalent to leuprorelin for Malignant neoplasms of breast Therapeutic equivalent to leuprorelin for Malignant neoplasms of prostate
  103. Vemurafenib General information
    Section
    Targeted therapies
    Indications
    Therapeutic equivalent to dabrafenib for Other specified melanoma of skin
  105. Vincristine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
    • Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)
    Indications
    Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Retinoblastoma Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis
  106. Vinorelbine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
    • Oral > Solid > capsule: 20 mg; 30 mg; 80 mg
    Indications
    Other specified malignant neoplasms of breast Other specified malignant neoplasms of bronchus or lung Rhabdomyosarcoma primary site
  107. Zanubrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 80 mg
    Indications
    Mantle cell lymphoma Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  108. Zoledronic acid General information
    Section
    Supportive medicines
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Malignant neoplasm metastasis in bone or bone marrow